Skip to main content
Equibles
FDMT logo

FDMT · 4D Molecular Therapeutics, Inc. · Analyst Estimates

Track FDMT — free

Use FDMT with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research FDMT.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.93 +0.97 (+8.11%) At close · Oct 28
Russell 2000 member Rebalance outlook locked
Market Cap
$863.27M
Shares
72.18M
Volume · Oct 28 1.19M Avg daily vol (3M) 996.07K

Analyst Estimates

Compare analyst forecasts for 4D Molecular Therapeutics, Inc. across metrics and forecast periods.

Estimates are grouped by forecast period, with low, average and high together. A dash means that statistic is not available.

Compiled consensus

These figures are a compiled consensus of analyst forecasts, not a survey the company published itself. Every figure is the statistic the source states; averages are means, never medians.

Captured 2026-10-20 19:28 UTC · Publication dates shown per estimate · 8 metric / period groups

FY ending 2026-12-31

Analyst estimates for FY ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-4.30
-4.15
-4.00
11
-4.15
-4.14
-4.14
-3.93
0
0
0
1
Revenue
USD
Publication date not stated
6.80M
13.26M
22.50M
10
 — — — — — — — —

FY ending 2027-12-31

Analyst estimates for FY ending 2027-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-4.94
-4.09
-3.38
10
-4.09
-4.09
-4.09
-3.77
1
2
0
0
Revenue
USD
Publication date not stated
0.00
20.63M
43.60M
8
 — — — — — — — —

Q ending 2026-09-30

Analyst estimates for Q ending 2026-09-30
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.10
-1.05
-0.99
11
-1.05
-1.04
-1.04
-1.01
1
1
0
1
Revenue
USD
Publication date not stated
0.00
3.10M
5.60M
8
 — — — — — — — —

Q ending 2026-12-31

Analyst estimates for Q ending 2026-12-31
Metric Low Average High Analyst count Average, 7 days ago Average, 30 days ago Average, 60 days ago Average, 90 days ago Estimates lowered, last 7 days Estimates lowered, last 30 days Estimates raised, last 7 days Estimates raised, last 30 days
EPS
USD
Publication date not stated
-1.23
-1.06
-0.95
11
-1.06
-1.03
-1.03
-1.00
1
1
0
1
Revenue
USD
Publication date not stated
0.00
3.87M
10.00M
8
 — — — — — — — —
Key facts CIK 1650648 CUSIP 35104E100 13F (30d) 22 filings 22 filers Visit website Investor relations